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Abstract
Background: Laryngeal dystonia is a task-specific focal dystonia of the internal laryngeal muscles.
Methods: Peer-reviewed articles on laryngeal dystonia from PUBMED were identified. Manuscripts that supported selected points of discussion were chosen.
Illustrative figures and videos from the authors’ personal files support selected ideas.
Results: This manuscript presents a comprehensive overview of the diagnoses and treatment of laryngeal dystonia and includes a brief history of the terminology,
genetic mutations, and common misdiagnosis. In addition, the manuscript provides an in-depth description of the use of botulinum toxin (BoNT), including the
mechanism of action, techniques for injections, and outcomes.
Discussion: Laryngeal dystonia is a complex clinically heterogeneous disorder. BoNT injection provides targeted therapy to the laryngeal muscles and has shown
great efficacy in improving voice fluidity. Nevertheless, BoNT provides only symptomatic relief without altering the underlying disorder. Future therapeutic options
that target the central nervous system may help clinicians better understand the pathophysiology of this condition.
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Introduction
Laryngeal dystonia is a clinical syndrome characterized by
involuntary hyperfunctional contraction of the internal laryngeal
muscles. The prominent feature of laryngeal dystonia is task specificity.
Speaking is the most commonly affected task and is referred to as
spasmodic dysphonia (SD). SD generally comes in two subtypes:
adductor SD and abductor SD. Adductor SD is caused by inappro-
priate hyperadduction of the vocal folds leading to a strained and
strangled voice quality. Adductor SD is five times more common than
abductor SD.1 Abductor SD is caused by inappropriate hyperabduc-
tion of the vocal folds and is heralded by intermittent breathy
phonation when attempting to articulate voiceless consonants.
Throughout the years the etiology, terminology, characteristics, and
treatment of SD have been debated. In this manuscript we present a
comprehensive overview of laryngeal dystonias beginning in 1871 when the
condition was first described by Taube. We have also included exemplary
figures and videos, which give support to understanding the disorder and
help differentiate it from other common laryngeal movement disorders.
Methods
The authors reviewed the literature onlaryngeal dysphonia. Peer-
reviewed articles from PUBMED were identified. Additional books and
supportive manuscripts were supplemented. Articles that best-support
points of discussion were chosen. Illustrative figures and videos from the
authors’ personal files have been included to support selected ideas.
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History and terminology
In 1871, Taube was the first to characterize SD when he described a
‘‘hysterical’’ girl with strained high-pitched hoarseness and called the
disorder ‘‘spastic dysphonia’’.2 Not yet recognized as a dystonia, the
disorder was thought to be a result of muscular spasticity. Since that
time the disorder has been described under multiple names, including
spastic aphonia, lalophobia, aphthongia, and psychophonasthenia.3–8
In 1887, Frankel noted a correlation between SD and another dystonic
disorder, mogigraphia (occupational writers’ cramp). He therefore
called the disorder mogiphonia.3,9 In 1973, Aronson was the first to
group the disorder into the two subtypes, adductor subtype and
abductor subtype, and in 1981 Aronson and Hartman recognized the
disorder to be associated with a vocal tremor.10,11
Blitzer emphasized that the term ‘‘spastic dysphonia’’ was in-
correct.12 While spasticity is restricted voluntarily movement resulting
from increased muscle tone, spasticity shows resistance to passive
movement and is not task specific. Dystonic contractions are task-
specific action-induced muscle spasms. Reciprocal inhibition results in
co-contraction of opposing agonist and antagonist muscles. Restriction
to passive movement is not seen in dystonia. In 1985 Blitzer used
laryngeal electromyography (LEMG) to confirm SD as a dystonic
disorder. Thus, the most accurate description of the disorder is ‘‘focal
laryngeal dystonia.’’12 In keeping with the spirit of Taube’s originally
coined term, the disorder was renamed ‘‘spasmodic dysphonia.’’ While
‘‘laryngeal dystonia’’ broadly describes involuntary dystonic contrac-
tures to the laryngeal muscles without identifying the involved task, SD
refers to laryngeal dystonia triggered by speech.
Epidemiology
SD is a rare disorder, and it is difficult to estimate its exact prevalence.
According to the National Spasmodic Dysphonia Association, approxi-
mately 50,000 people in North America are affected by SD, with an
estimated prevalence of 0.009%.13,14 Taking into account that SD is
often misdiagnosed, the true prevalence is likely somewhat higher. The
majority of cases are in women (63%), and most (82.5%) are classified as
primary idiopathic. The average age of onset is 39 years of age.1 The
first attack of SD may occur suddenly or can be triggered by a seemingly
unrelated occurrence, such as trauma,15–18 or viral illness.19,20 Trauma
is accepted as the inciting trigger when the onset of the dystonia occurs
within 6–12 months of an identified injury. In some cases, the injury
may be so mild that it is overlooked.21
Secondary SD is caused by a known underlying source. In most
cases, secondary SD is due to a neurological disease, such as Wilson’s
disease, multiple sclerosis, or storage diseases. Rarely life-threatening,
laryngeal dystonia occurs as an adverse side effect to certain
neuroleptic medications.22,23
Genetics
While the cause of SD is still unknown, 20% will have a known
dystonia gene mutation and 12% of patients will have a positive family
history.1 Hereditary dystonias are usually autosomal dominant and less
frequently autosomal recessive or X-linked.
Genetic mutations are entitled ‘‘DYT,’’ which stands for dystonia.
DYT1 is caused by a mutation to torsinA and is the most common genetic
cause of dystonia.24–29 Although the role of torsinA in cellular function is
not fully understood, its amino acid sequence is similar to that of heat
shock proteins. Patients with DYT1 mutations present with early-onset
dystonia before 10 years of age, and affected children usually progress to a
more generalized dystonia.26 Most DYT1 mutations are autosomal
dominant; however, reduced penetrance within families may occur with
some carriers having no clinical symptoms. DYT1 mutations are five to
10 times more common in the Ashkenazi Jewish population,30–34 and
10–20% of patients will have voice symptoms.
A mutation to the tubulin beta-4A (TUBB4A) gene is associated with
DYT4. Beta tubulin is primarily expressed in the central nervous system
where it forms heterodimers with alpha-tubulin and is responsible for
microtubule assembly. The mutation was first reported as ‘‘whispering
dystonia’’ with autosomal dominant inheritance in an Australian family.35
Patients in this family also have characteristics of Wilson’s disease.36 The
observed whispering phenomenon has been recognized as adductor SD
with compensatory whispering as a response to involuntary laryngeal
hyperadduction. DYT4 dystonia also commonly affects the face and many
will eventually develop generalized dystonia and dysphagia.
Mutations to the thanatos-associated protein domain containing
apoptosis associated protein 1 (THAP1) have been identified as the
basis for DYT6 dystonia. THAP1 is expressed in both the central and
the peripheral nervous systems and is involved in transcriptional
regulation, apoptosis, and cell-cycle control. The mutation was first
recognized in Amish-Mennonites in the United States and has since
been identified in a multitude of familial and sporadic cases from
different racial and ethnic groups.37–40 Inheritance is autosomal
dominant with reduced penetrance and variable expressivity. Mutations
to THAP1 are associated with adductor laryngeal dystonia.37,41,42 The
first signs of DYT6 dystonia are usually in the larynx, face, and neck
with eventual progression towards segmental or generalized dystonia.
DYT25 is associated with a mutation in the guanine nucleotide binding
protein alpha activating polypeptide (GNAL) gene. GNAL is involved in
dopamine type 1 receptor function and olfactory signal transduction.37
Inheritance is autosomal dominant and affected family members present
with cervical or cranial–cervical dystonia. A few sporadic cases with
similar phenotypes have also been reported.43–45 Forty percent of patients
with DYT25 mutation will also develop SD.44,46
Although there are already 27 known DYT gene mutations, reduced
penetrance, variable expressivity, and rarity of this disorder make it
difficult to provide the exact genetic or inherited prevalence.47 Dystonia
that is without a known genetic mutation or secondary cause is labeled as
idiopathic. However, neither negative family history nor negative genetic
testing can definitively exclude a genetic cause. Negative family history
may result from reduced penetrance, late onset, early death, or a
spontaneous mutation. It is also likely that some mutations have yet to be
identified. We recently presented a review of 57 patients with isolated
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laryngeal dystonia and found no carriers of TOR1A (DYT1), TUBB4A
(DYT4), or THAP1 (DYT6) mutations. One patient was a carrier of
a GNAL (DYT25) mutation without a familial history of dystonia.
Clinical characteristics
Patients with laryngeal dystonia have normal development and
intellect. About 15% of patients with focal laryngeal dystonia will
eventually develop dystonic contractions in areas other than the larynx.1
SD is the most common laryngeal dystonia. Although conversational
speech is affected, breathing, coughing, laughing, yelling, crying, singing,
and swallowing are normal. SD generally falls into one of two broad
categories: adductor SD and abductor SD. Although rare, there are also
cases of mixed SD showing characteristics of both adductor and abductor
SD. Patients with SD often have an associated vocal tremor resulting from
co-contraction of opposing muscle groups. Unlike the vocal tremor in
essential tremor, the vocal tremor in SD is irregular. In some patients the
vocal tremor can be subtle and may be overlooked on examination.
Adductor spasmodic dysphonia
Adductor SD involves contracture of the laryngeal muscles respon-
sible for closing the vocal folds. These include the thyroarytenoid (TA),
lateral cricoarytenoid (LCA), transverse arytenoid, and possibly the
cricothyroid muscles (Figure 1A,C). Patients with adductor SD have
difficulty when articulating consonants that require vocal closure.
Clinically they have a choked, strained, and strangled voice with voice
breaks during phonation. Glottic closure during swallowing and
coughing are uninvolved. The laryngeal examination can be subtle or
may show hyperfunctional closure of the true and false vocal folds or
excessive vocal fold tension with voicing that normalizes with other tasks
such as coughing, breathing, or swallowing (Video 1).
Abductor spasmodic dysphonia
Abductor SD involves contracture of the posterior cricoarytenoid (PCA)
muscles, which are the sole muscles responsible for opening the glottis
(Figure 1B, C). When phonating a voiceless consonant (/h/, /p/, /t/)
Figure 1. Intrinsic Laryngeal Muscles and Effect on Vocal Fold Position. Intrinsic muscles of the larynx (A,B) and the movement of the vocal folds caused by
their contraction (C). Dashed lines indicate position of vocal folds and arytenoid cartilages before movement caused by contraction of the muscles (arrows). Solid lines
indicate position of vocal cords and arytenoid cartilage after contraction. Cricothyroid muscle, 1 and 2 indicate movements of cartilages. With permission from Cooper
MH. Anatomy of the Larynx In: Blitzer A, Brin MF, Sasaki CT, Fahn S, Harris K, editors. Neurological disorders of the larynx. New York: Thieme; 1992. p 6.
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the glottis must open widely. The vocal folds of patients with abductor SD
persist in the open position resulting in a prolonged, effortful, aphonic, and
breathy voice quality. The laryngeal examination may show hyperfunc-
tional abduction of one or both vocal folds and voicing with normal glottic
opening during inspiration or coughing (Video 2).
Mixed and compensatory spasmodic dysphonia
Some patients show characteristics of both adductor and abductor
SD, which makes diagnosing the correct SD subtype challenging. The
diagnosis of mixed SD is often made when one subtype gets worse or is
revealed following successful treatment of the other subtype. Patients
with mixed SD often require treatment to both adductor and abductor
muscles.1 We have also observed patients convert from pure adductor
SD to pure abductor SD, and the other way around, following years of
successful treatment.
Some patients have compensatory behaviors to a particular SD
subtype and are mistakenly categorized as having mixed SD. For
instance, compensatory pseudo-abductor dysphonia occurs when
patients with adductor SD initiate words with a whisper to prevent
the onset of adductor spasms while voicing. This was recognized as the
phenomenology in DYT4 dystonia. Compensatory pseudo-adductor
dysphonia is less common. In this instance, patients with severe
abductor SD phonate before voiceless consonants to overcome
involuntary breathy voice breaks.48–50
Cannito and Johnson51 proposed that SD should be seen on a
continuum and cannot be placed neatly into strict categories such as
adductor SD, abductor SD, or mixed SD. They suggest that an
individual’s symptomatology depends on their directional preponder-
ance. Findings by Hillel52 also suggest that SD may be a more
heterogeneous disorder. He found that patients with adductor,
abductor, and mixed SD each have abnormal LEMG signals in all
intrinsic laryngeal muscles during both phonatory and non-phonatory
tasks.
Task specificity
The prominent feature of laryngeal dystonia is that of task
specificity. Speaking is the most commonly affected task with
preservation of a normal cough, laugh, and singing voice. Less
commonly, alternate laryngeal tasks are implicated. We have reported
on cases of respiratory adductor laryngeal dystonia where involuntary
vocal fold adduction occurs upon inspiration.53–56 These patients have
normal laryngeal function when speaking, singing, coughing, and
swallowing.
Occupational dystonia
The term occupational dystonia refers to the development of dystonic
movements to highly skilled tasks usually involving a repetitive motor
activity.57,58 Musicians are often affected. Although the precise pathophy-
siology of occupational dystonia remains unclear, observations of musicians
suggest that increased corticospinal excitability and reduced cortical
inhibition play a role.59–61 The observed sensorimotor reorganization likely
facilitates the acquisition of uninhibited motor skills necessary in expand-
ing a musician’s creativity at the expense of potentially developing a focal
dystonia while playing an instrument.62–66 We have reported on cases of
‘‘singer’s dystonia,’’ where patients have a fluent voice quality with
conversational speech and laryngeal hyperkinesias solely with singing.67,68
‘‘Singer’s dystonia’’ is viewed as an occupational dystonia.
Sensory trick
Geste antagonistique, or sensory trick, consists of maneuvers that
stimulate tactile proprioceptive signals and temporarily ameliorate
Video 1. Adductor Speech and Laryngeal Examination. Patients with
adductor spasmodic dysphonia. Note the normal appearance to the larynx
prior to phonation. This patient has a strained and strangled voice with voice
breaks.
Video 2. Abductor Speech and Laryngeal Examination. Patients with
abductor spasmodic dysphonia. Note the normal appearance to the larynx prior to
phonation and with breathing. This patient has breathy voice breaks with
phonation. She has normalization of voice with voiced consonants and severe
whispered voice breaks with voiceless consonants.
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the dystonic movements.69 While the physiological mechanism of the
sensory tricks is unknown, it is likely a result of temporary alterations to
the afferent feedback.70,71 Patients with SD have reported improved
symptoms by various maneuvers, including pinching the nares, placing
pressure on their head, abdomen, or clavicle, or pulling their ear.72,73
The sensory trick is such a powerful exercise that some patients have
reported reduced dystonic activity by simply thinking of their
particular sensory trick.74 Over time, the sensory trick generally loses
its effectiveness. The reason for this is also unknown, but is likely a
result of central nervous system adaptation. The video below depicts a
patient with adductor SD who achieves fluidity of speech with palatal
elevation (Video 3).
Pathophysiology
Although the clinical symptoms in laryngeal dystonia are well
described, the pathophysiology of the disorder is unknown. Task
specificity suggests a central cause. SD likely involves abnormalities to
areas in the brain responsible for learned voice production, explaining
why areas responsible for innate vocalizations, such as crying and
laughing, are unaffected. Recent studies have demonstrated altered
brain activity by functional magnetic resonance imaging (fMRI) in
patients with SD compared with normal controls.75 Laryngeal
feedback to the brain was the most impaired function and may play
a key role. Surprisingly, differences in brain activity were noted during
both symptomatic and asymptomatic tasks. Structural differences
connecting the cortex to the brain stem were also observed in patients
with SD.76
Diagnosis
The diagnosis of SD is made primarily on the perceptual analysis of
the voice in the absence of secondary causes. Laryngeal examination
may show hyperadduction or prolonged abduction of the vocal folds
with phonation but may also be normal. Although LEMG may show
intrusion of spasmodic bursts, these findings are not consistently found
in all patients.12 Currently, the use of imaging is limited to scientific
research studies. As such, there are no good objective studies to
diagnose SD. Making the correct diagnosis relies on an experienced
clinician with a good ear.
Alternate diagnosis
As stated above, the diagnosis of SD is ultimately made from
patients’ clinical symptomatology and relies on an experienced
physician with a trained ear. Objective studies may be normal,
making it difficult to differentiate SD from other laryngeal voice
disorders like essential vocal tremor, or muscle tension dysphonia.77
Vocal tremor
The vocal tremor in SD is a result of isometric co-contraction of
antagonistic muscles. However, vocal tremors can be seen in other
disorders such as essential tremor, Parkinson’s disease, Tourette’s
syndrome, vocal tics, cerebellar ataxia, and flaccid dysarthria.78–80
Vocal tremor in SD is a consequence of loss of reciprocal inhibition
resulting in an irregular isometric tremor. Essential laryngeal tremor is
characterized by reciprocal oscillatory movement of antagonistic
muscles and shows regular rhythmic 4–12 hertz frequency tremors.
Laryngeal examination often shows vertical or horizontal movement of
the larynx with speaking or with quiet respirations81–84 (Video 4).
Although much less common, periods of co-contraction have been
reported in essential tremor and regular periodic tremors have been
observed in SD.12
Muscle tension dysphonia
Muscle tension dysphonia occurs when patients squeeze the
laryngeal muscles while speaking. Patients often produce voice with
muscles that are not meant for voice production. Excessive laryngeal
squeezing causes a strained, tight, and tense voice quality that could be
mistaken for adductor SD. Most commonly, misuse includes vibration
of the ventricular vocal folds (false vocal folds). Patients may also
incorporate muscle activity from the laryngeal strap muscles or the
sternocleidomastoid muscles and may report tenderness of the cervical
muscles.85 Laryngeal muscle misuse generally develops as a persistent
adaptation to a temporary injury, infection, or paresis. In most
instances, the diagnosis of muscle tension dysphonia can be made by
physical examination findings. Muscle tension dysphonia is best
treated with voice therapy. Infrequently we have injected botulinum
toxin (BoNT) into the ventricular vocal folds in cases of severe
refractory muscle tension dysphonia (Video 5).
Treatment
Surgery
In 1976, Dedo86 reported normalization of voice quality following
unilateral section of the recurrent laryngeal nerve (RLN). Surgery
was performed with hopes of relieving aberrant laryngeal muscle activity
at the cost of unilateral vocal fold paralysis. Initial studies reported an
85–90% success rate; however, a 3-year follow-up showed that 64% of
patients had a return of pathologic voice quality.87–89 Several procedures
designed to mechanically relax the vocal folds through alterations in the
laryngeal framework also failed to demonstrate long-term success.90,91
Video 3. Sensory Trick. This video depicts a patient with adductor spasmodic
dysphonia who can achieve fluidity of voice with palatal elevation.
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Part of the dramatic initial improvement seen with surgery could be
attributed to acute alterations in peripheral proprioceptive signals similar
to a sensory trick. Nevertheless, the peripheral alteration is fixed, and
central adaptation may explain the high rate of recidivism.
In 1986, Blitzer found dramatic improvement in voice quality
following direct injection of BoNT into the affected laryngeal
muscles.48 Unlike neuronal surgery, BoNT injection is selective. In
addition, the toxin is continuously metabolized, thus the ever-changing
effect does not allow for central adaptation. However, the response to
BoNT is temporary, necessitating repeat injection. In an attempt to
provide permanent selective denervation, Berke et al.92 performed a
selective denervation–reinnervation procedure. The branches of the
RLN responsible for innervating only the adductor laryngeal muscles
were cut and then anastomosed to a branch of the ansa cervicalis.92
Critics of RLN transection claimed that recidivism resulted from
persistent hyperadduction from the unaffected nerve. Berke thus
performed the denervation–reinnervation procedure bilaterally, and
the procedure was only performed in patients with adductor SD.
Although initial results are promising, long-term results show the
return of voice breaks in 26% and a breathy voice quality in 30%.93
Voice therapy
Voice therapy may be useful in preventing unwanted compensatory
voice patterns and results are usually discouraging.94
Systemic oral medications
Systemic medications generally act on the central nervous system
and reduce excess muscle and nerve activity. Although the medications
discussed below are commonly used in SD, none is approved by the
United States Food and Drug Administration for use in dystonia.
Anticholinergic agents act centrally and peripherally, and although they
are the most successful systemic medications their side-effects (flushing,
hyperthermia, dry skin, urinary retention, tachycardia, confusion, agitation,
and hallucinations) are not always tolerated.95 The most commonly
used medications in dystonia act centrally on gamma-aminobutyric acid
(GABA) neurotransmitters (benzodiazepines, baclofen, and gabapen-
tin).95,96 Common side effects of these medications include sleepiness,
depression, loss of balance, and confusion. Medications that modulate
GABA must be used with caution as they carry a risk of dependence, and
sudden withdrawal could incite serious life-threatening complications such
as seizures.97–99 Levodopa, commonly used in treating Parkinson’s disease,
increases centrally available dopamine and is occasionally also used in
dystonia.95 Carbidopa, often used in combination with levodopa, inhibits
the peripheral conversion of levodopa and reduces the peripheral side
effects of dopamine.
No systemic oral medication is uniformly effective in treating
laryngeal dystonia, and they are mostly used adjectively to prolong the
duration of BoNT.
Botulinum toxin
The gold standard for treatment of laryngeal dystonia is EMG-
guided BoNT injections directed to the affected muscle.
Mechanism of action
BoNT is a 150-kD exotoxin produced from Clostridium botulinum,
whose action is mediated through the cleavage of docking proteins
responsible for membrane fusion of pre-synaptic vesicles. Type A botu-
linum toxin (BoNT-A) cleaves the membrane-associated protein
‘‘synaptosomal-associated protein’’25 (SNAP-25), which is a member
of the ‘‘soluble N-ethylmaleimide-sensitive factor attachment protein C
receptor’’ (SNARE) protein. Type B botulinum toxin (BoNT-B)
cleaves synaptobravin, which is part of the vesicular-associated
membrane protein. Cleavage of these docking proteins leads to
inhibition of acetylcholine release at the neuromuscular junction, and
subsequent muscle weakness.
Video 4. Essential Vocal Tremor. Note the oscillatory rhythmic vertical and
horizontal movement of the larynx with a sustained phonation in this patient with
essential vocal tremor. The patient has adapted quick bursts of staccato speech
and voices in-between rhythmic tremors to mask her disorder. Also note the
presence of a tremor at both arytenoids during quiet respiration.
Video 5. Muscle Tension Dysphonia Speech and Laryngeal Examination.
Laryngeal exam of a patient with severe muscle tension dysphonia with sphincteric
supraglottic squeezing and a strangulated voice quality. Notice that voice fluidity is
improved following exercises that loosen his laryngeal muscles.
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Chemodenervation of aberrant laryngeal muscle activity does not
fully explain the clinical effects of BoNT in SD, as evidenced by the
efficacy of unilateral injections. The likely effect of BoNT also includes
modulation to the afferent sensory feedback from peripheral muscles to
the central nervous system.100–102 BoNT also decreases the activation
of muscle spindles directly through its effect on intrafusal afferent
sensory fibers.103,104 Lastly, the effect of BoNT is constantly changing
over the course of 12 weeks, making central adaptation difficult.105
If the effect of BoNT also imposes a sensory trick, then the effect will
be sustained throughout the entire biological activity of the toxin.
Injection technique
The most common approach to BoNT laryngeal injections is via
transcutaneous EMG-guided needle injection to the affected laryngeal
muscle. We advocate using low-volume injections to prevent diffusion
to neighboring muscles, which can lead to unnecessary side effects.106
Patient follow-up is 2 weeks after the initial injection for dosage
adjustment. Once an effective dose is established, patients generally
follow-up every 12 weeks for repeat injections. SD, like all dystonias, is
a dynamic disorder and the severity of symptoms may progress or
improve over time. We therefore make dose adjustments at every
follow-up visit on the basis of each individual patient’s symptoms.
The TA or LCA muscles are targeted for adductor SD (Figure 1A).
The most common approach is through the cricothyroid membrane
and injections are generally well tolerated. Our initial dose is 1 unit to
each TA or LCA, and the dose is adjusted on subsequent visits. On
average, the response to therapy begins 2.4 days after TA/LCA
injection1 (Video 6).
The PCA muscle is targeted for abductor SD (Figure 1B). The larynx is
rotated and injection is achieved transcutaneously through the pyriform
sinus. EMG confirmation is obtained with the electrode against the
posterior cricoid cartilage while the patient abducts their vocal folds by
sniffing though their nose ( i.e., PCA contraction) (Figure 1C). In difficult
cases, access to the PCA can be achieved transcutaneously through the
cricothyroid membrane. In such cases, the injection needle is extended
into the lumen of the subglottis and directed 30 degrees off midline
towards the posterior cricoid ring. The posterior cricoid cartilage is
punctured, and BoNT is injected upon EMG confirmation from the
PCA. Before every PCA injection, we perform a dynamic laryngeal
examination to assess airway patency. We only perform unilateral
injections to the PCA and inject the more active side to prevent excessive
airway narrowing. Our starting dose is 3.75 units. High-dose injections
risk excessive airway narrowing and in rare cases may necessitate
tracheotomy. High-volume injection may diffuse inferiorly and may risk
dysphagia from effects to the cricopharyngeal muscle. On average, the
response to therapy begins 4.1 days after PCA injections1 (Video 7).
Outcomes
In general patients have good clinical responses to BoNT, and they
are able to regain the fluidity in their voice (Video 8). In our series of
901 patients treated for over 12 years (6,280 sessions), we found that
patients with abductor SD do not achieve the same degree of voice
normalization as adductor SD patients.1 Patients with abductor SD
reported improvement to 66.7% of normal function lasting on average
10.5 weeks compared with nearly 90% of normal function lasting on
average 15.1 weeks in patients with adductor SD. It is therefore not
surprising that 30% of patients with abductor SD supplement BoNT
injections with systemic oral medication.106
Novakovic et al.105 found that 28.5% of patients with adductor SD will
have an initial decline of function with a breathy voice quality before
improving (Figure 2B). The initial functional decline lasts approximately
2 weeks and they are at risk of aspiration during this period.1,106 Voice
quality generally normalizes thereafter with maximal benefit sustained
over approximately 6 weeks. This period is followed by a slow decline
Video 6. Cricothyroid Injection Technique for Adductor Spasmodic
Dysphonia. Transcutaneous electromyography (EMG)-guided botulinum toxin
injection into the thyroarytenoid muscles through the cricothyroid membrane.
Note confirmation of intramusclar placement by audible EMG signal.
Video 7. Posterior Cricoarytenoid Injection Technique for Abductor
Spasmodic Dysphonia. Transcutaneous botulinum toxin injection into the
posterior cricoarytenoid. The larynx is rotated and injection is achieved through
the pyriform sinus. Electromyography confirmation is obtained while the patient is
asked to sniff.
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over 4 weeks.105 Although not all patients responded with an initial
decline of function, those who did ultimately achieved a higher percentage
of normal function than those who did not (Figure 2A, B).
Poor clinical response to BoNT occasionally occurs and is usually due
to inadequate dosing, inappropriate technique, or dynamic changes of
the underlying laryngeal dystonia. Injection of supraglottic muscles, the
cricothyroid muscle, or transverse arytenoid musclehas demonstrated
some benefit in refractory cases.107,108 In rare instances, patients with SD
may become secondarily non-responsiveness to BoNT following an initial
good response. This effect likely results from the development of anti-
BoNT antibodies.109–111 Over time and following the removal of the
antigenic stimulus, patients will revert back to negative antibody status
and have a good clinical response to re-injections. During the cessation
period, patients will respond well to BoNT injection of a different
serotype. Clinicians should be aware that different BoNT serotypes have
their own dosing regimen, onset, and duration.112
Future therapeutic options
A recent survey showed that 55.9% of patients with SD have
improvement of voice following ingestion of alcohol.113 In this study, the
duration of benefits was between 1 and 3 hours, with the maximal effect
occurring after two drinks. The effect of alcohol in SD may be related to
the effect of alcohol on GABA receptors. A metabolite of sodium oxybate,
used to treat excessive daytime sleepiness in narcolepsy, also acts on GABA
receptors and is currently being investigated in treating selected patients
with SD whose dystonia improves following ingestion of alcohol.114–117
Figure 2. Vocal Function Over Time. The above graph represents percentage of normal voice function from the time of initial Botulinum Toxin Injection against time. Two
general configurations are represented. (A) Type I curves shows 80% normal voice function in the plateau phase without initial breathiness. (B) Type II cures show an initial decline
of function, but patients ultimately achieved higher percent of normal function in the plateau phase. B, Baseline; B1, Return to Baseline; P1–P2, Plateau Phase; P2-D, Decline Phase.
Video 8. Before and After Botulinum ToxinInjection. This video depicts
a patient with abductor spasmodic dysphonia before and after botulinum toxin
injection. Note that the patient has severe breathy voice breaks before injection
and has regained fluidity of his voice following botulinum toxin injection.
Mor N, Blitzer A Diagnosis and Treatment of Laryngeal Dystonia
Tremor and Other Hyperkinetic Movements
http://www.tremorjournal.org
The Center for Digital Research and Scholarship
Columbia University Libraries/Information Services8
Scientists are searching formore efficient forms of BoNT with improved
efficacy at a lower therapeutic dose.118,119 Future developments in bio-
engineering will likely unleash recombinant neurotoxins capable of in-
creased specificity for targeting only certain cells or areas of the body.
Conclusion
Laryngeal dystonia is a task-specific focal disorder of the central
nervous system that affects the laryngeal muscles. Spasmodic dysphonia
is when laryngeal dystonia affectsvolitional speech. Mechanical altera-
tions temporarily elude the central nervous system and abolish the
aberrant signal. However the brain eventually adapts to static changes.
BoNT injection provides targeted therapy to the laryngeal muscles and
has shown great efficacy in improving voice fluidity. Nevertheless, BoNT
provides only symptomatic relief without altering the underlying disorder.
Future therapeutic options that target the central nervous system may
help clinicians better understand the pathophysiology of SD and may add
to our therapeutic armamentarium.
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